HIV Infections
Conditions
Keywords
Anti-Infective Agents, Quinolone, Ofloxacin, Acquired Immunodeficiency Syndrome
Brief summary
To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
Interventions
DRUGLevofloxacin
Sponsors
R W Johnson Pharmaceutical Research Institute
Study design
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have the following: HIV infection.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active opportunistic infection or neoplasm. * High likelihood of death during study. * Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease. * Donation of \> 1 unit blood or acute loss of blood within one month of study entry. Patients with the following prior conditions are excluded: * History of opportunistic infection. * Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone. Prior Medication: Excluded: Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.
Countries
United States
Outcome results
None listed